Theragen Etex Co has a quick ratio of 1.14. It generally indicates good short-term financial strength.
The historical rank and industry rank for Theragen Etex Co's Quick Ratio or its related term are showing as below:
XKRX:066700'
s Quick Ratio Range Over the Past 10 Years
Min: 1.06 Med: 1.2 Max: 1.71
Current: 1.14
During the past 13 years, Theragen Etex Co's highest Quick Ratio was 1.71. The lowest was 1.06. And the median was 1.20.
XKRX:066700's Quick Ratio is ranked worse than 59.39% of 1017
companies
in the Drug Manufacturers industry
Industry Median: 1.4
vs XKRX:066700: 1.14
Theragen Etex Co Quick Ratio Historical Data
The historical data trend for Theragen Etex Co's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Theragen Etex Co's Quick Ratio
For the Drug Manufacturers - Specialty & Generic subindustry, Theragen Etex Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theragen Etex Co's Quick Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Theragen Etex Co's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Theragen Etex Co's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Theragen Etex Co's Quick Ratio for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theragen Etex Co (XKRX:066700) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Theragen Etex Co Quick Ratio Related Terms
Thank you for viewing the detailed overview of Theragen Etex Co's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Theragen Etex Co Ltd is a Korea-based company mainly engaged in the manufacturing and selling of finished pharmaceutical products and providing genome sequencing services. It also provides healthcare services. The company's operating segments include its Pharmaceutical business and the Healthcare and Genome Analysis Business. A majority of its revenue is generated from the Pharmaceutical Business which involves the manufacturing and sales of specialized and general medicine along with new drug research and development. The Healthcare and Genome Analysis Business involves DNA sequence analysis, RNA mutation genome analysis and decoding, and the distribution of non-prescription drugs for healthcare purposes. Geographically, the company derives its key revenue from the domestic market.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XKRX:066700 has been successfully added to your 